FDA Approved: UMECLIDINIUM AND VILANTEROL ELLIPTA — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Umeclidinium bromide and vilanterol triflate Ellipta, submitted by Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• UMECLIDINIUM AND VILANTEROL ELLIPTA (umeclidinium bromide and vilanterol triflate)

Snippet

SUPPL AP for UMECLIDINIUM AND VILANTEROL ELLIPTA (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE)